Biogen Inc. (LON:0R1B)
141.67
-0.22 (-0.15%)
At close: Sep 8, 2025
Biogen Revenue
Biogen had revenue of $2.65B USD in the quarter ending June 30, 2025, with 7.33% growth. This brings the company's revenue in the last twelve months to $10.00B, up 3.36% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$10.00B
Revenue Growth
+3.36%
P/S Ratio
2.10
Revenue / Employee
$1.31M
Employees
7,605
Market Cap
15.30B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Biogen News
- 15 hours ago - Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 days ago - Biogen (BIIB) Analyst Ratings Update: September 4, 2025 | BIIB Stock News - GuruFocus
- 5 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 5 days ago - Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
- 6 days ago - Biogen (BIIB) Seeks FDA Expansion for Alzheimer's Drug Autoinjector - GuruFocus
- 6 days ago - Biogen, Eisai begin rolling FDA submissions for Leqembi injectable for starting dose - Seeking Alpha
- 6 days ago - Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - Benzinga
- 6 days ago - Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - GlobeNewsWire